We are live on ! Find out more
PLXP

PLx Pharma Inc. Common Stock
PLXP

Delisted

PLXP was delisted on the 12th of April, 2023.

Back to rankings

14 hedge funds and large institutions have $15.8M invested in PLx Pharma Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

7% less funds holding

Funds holding: 15 → 14 (-1)

7% less capital invested

Capital invested by funds: $17M → $15.8M (-$1.26M)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$273K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$104K
3
TCM
Timpani Capital Management
Wisconsin
+$66.7K
4
OC
Oppenheimer & Co
New York
+$66.1K
5
Morgan Stanley
Morgan Stanley
New York
+$3.36K

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$1.2M
2
SFM
Sphera Funds Management
Israel
-$916K
3
TRCT
Tower Research Capital (TRC)
New York
-$15.3K
4
Deutsche Bank
Deutsche Bank
Germany
-$15K
5
GSC
Ground Swell Capital
South Carolina
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Kingdon Capital Management
New York
$6.97M – – –
BC
2
Broadfin Capital
New York
$4.73M – – –
PRCM
3
Pine River Capital Management
Minnesota
$2.05M – – –
TCM
4
Timpani Capital Management
Wisconsin
$1.42M +$66.7K +873 +5%
Vanguard Group
5
Vanguard Group
Pennsylvania
$284K +$273K +3,573 New
OC
6
Oppenheimer & Co
New York
$204K +$66.1K +865 +51%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$108K +$104K +1,363 New
Morgan Stanley
8
Morgan Stanley
New York
$6K +$3.36K +44 +142%
BIM
9
BlackRock Investment Management
Delaware
$5K – – –
U
10
UBS
Switzerland
$5K – – –
Wells Fargo
11
Wells Fargo
California
$5K – – –
TRCT
12
Tower Research Capital (TRC)
New York
$2K -$15.3K -200 -89%
Citigroup
13
Citigroup
New York
$2K +$1.91K +25 New
FANJ
14
Financial Architects (New Jersey)
New Jersey
$1K – – –
GPP
15
Great Point Partners
Connecticut
– -$1.2M -15,516 Closed
SFM
16
Sphera Funds Management
Israel
– -$916K -11,800 Closed
Deutsche Bank
17
Deutsche Bank
Germany
– -$15K -197 Closed
GSC
18
Ground Swell Capital
South Carolina
– -$6K -76 Closed

PLXP Hedge Fund Activity: Q3 2014 in Review

14 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q3 2014, worth a combined $15.8M — down 7.4% from $17M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of PLXP and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, opening a new position worth an estimated $273K. The largest seller was Great Point Partners, exiting entirely with an estimated $1.2M sold.

  • 14 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q3 2014, down from 15 in Q2 2014.
  • Funds reported $15.8M of PLx Pharma Inc. Common Stock stock for Q3 2014, down 7.4% quarter-over-quarter.
  • 3 funds opened new PLx Pharma Inc. Common Stock positions in Q3 2014 and 4 closed out, a net change of -1 holder.
  • The largest PLx Pharma Inc. Common Stock buyer in Q3 2014 was Vanguard Group, an estimated $273K added.
  • The largest PLx Pharma Inc. Common Stock seller in Q3 2014 was Great Point Partners, an estimated $1.2M sold.

Based on aggregated 13F filings for Q3 2014.